Michael Lehnert
Papers
1
Total Citations
4
H-Index
1
About
Michael Lehnert is a leading figure in the development of centrifugal microfluidic technologies for clinical diagnostics, with a particular focus on liquid biopsy and cancer monitoring. His most notable contribution is the invention of the "MRD disk," a proof-of-principle centrifugal microfluidic platform that enables automated, highly sensitive, and multiplexed quantitative PCR (qPCR) for minimal residual disease (MRD) monitoring. This work, published in 2020 and garnering 4 citations, addresses a critical need in oncology: the standardization of repetitive, longitudinal assays requiring exceptional reproducibility and sensitivity. Lehnert’s innovation streamlines the detection of residual cancer cells after treatment, offering a pathway toward more precise and accessible patient monitoring. His research sits at the intersection of microfluidics, molecular diagnostics, and clinical translation, aiming to bridge the gap between lab-on-a-chip technology and routine clinical use. By demonstrating that centrifugal microfluidics can automate complex qPCR workflows without compromising sensitivity, Lehnert has laid the groundwork for next-generation point-of-care systems that could transform how clinicians track disease progression and treatment response.
Research Focus
Key Achievements
Top Papers
- 1